The cholinergic system mediates neuromuscular transmission, autonomic ganglionic transmission (sympathetic and parasympathetic preganglionic fibers and postganglionic parasympathetic), parasympathetic effector function, and major CNS cognitive and arousal functions. Therapeutically, cholinergic pharmacology spans dementia (acetylcholinesterase inhibitors), neuromuscular disease (myasthenia gravis), urinary control, antinauseant therapy, and anticholinergic side effects of countless medications. The cholinergic system also produces some of the most rapidly lethal toxicology in neurology — organophosphate and nerve agent poisoning. This page covers the anatomy, receptor pharmacology, and major drug classes.

Cholinergic Anatomy

Central

  • Basal forebrain cholinergic neurons: nucleus basalis of Meynert, medial septal nucleus, diagonal band of Broca → projections to cortex and hippocampus. Critical for attention, memory, arousal.
  • Pedunculopontine and laterodorsal tegmental nuclei: brainstem cholinergic nuclei; thalamocortical activation, REM sleep generation.
  • Local cholinergic interneurons (striatum).

Peripheral

  • Motor neurons (neuromuscular junction).
  • Preganglionic sympathetic and parasympathetic.
  • Postganglionic parasympathetic (M receptors at effectors).
  • Postganglionic sympathetic to sweat glands.

Cholinergic Receptors

Nicotinic (N)

  • Ligand-gated cation channels.
  • NM (muscle): neuromuscular junction; targeted by neuromuscular blockers (vecuronium, rocuronium, succinylcholine).
  • NN (neuronal/ganglionic): autonomic ganglia, CNS; target of nicotine, varenicline (smoking cessation).

Muscarinic (M)

  • G-protein coupled.
  • M1: CNS (cortical, hippocampal); cognition.
  • M2: heart (slows heart), CNS autoreceptors.
  • M3: smooth muscle, glands (bronchoconstriction, GI motility, exocrine secretion, urinary).
  • M4, M5: CNS (M4 striatum; M5 substantia nigra).

Cholinergic Synthesis and Metabolism

  • Synthesis: choline + acetyl-CoA → acetylcholine (choline acetyltransferase, ChAT).
  • Storage: vesicular acetylcholine transporter (VAChT).
  • Release: voltage-gated Ca²⁺ → vesicle fusion → exocytosis.
  • Degradation: acetylcholinesterase (AChE) in synaptic cleft → choline + acetate; rapid (allows precise neuromuscular control).
  • Butyrylcholinesterase (BChE): plasma esterase; broader substrate; relevant for some drug metabolism.

Major Drug Classes

Acetylcholinesterase Inhibitors (Central)

For Alzheimer dementia and dementia with Lewy bodies:

  • Donepezil: long half-life, once-daily; widely used.
  • Rivastigmine: oral or transdermal patch; less GI, useful in PD dementia and DLB.
  • Galantamine: also nicotinic allosteric modulator.
  • Mechanism: prolong synaptic ACh by inhibiting AChE.
  • Side effects: nausea, vomiting, diarrhea, bradycardia, syncope (especially in patients with conduction disease), GI cramps, muscle cramps, nightmares.
  • Modest cognitive benefit in mild-moderate AD; benefit declines in severe disease.
  • Cost-effectiveness debated; symptom modifiers, not disease modifiers.

Acetylcholinesterase Inhibitors (Peripheral/MG)

  • Pyridostigmine: oral, mainstay of MG symptom management; q4-6h dosing.
  • Neostigmine: IV; also for reversal of neuromuscular blockade in anesthesia.
  • Edrophonium: short-acting; historical Tensilon test for MG (largely abandoned for ICE-pack or seroconversion testing).
  • Side effects: muscarinic excess (SLUDGE: salivation, lacrimation, urination, defecation, GI motility, emesis); cholinergic crisis in overdose.

Nicotinic Receptor Modulators

  • Varenicline: partial agonist at α4β2 nicotinic receptors; smoking cessation; FDA-approved.
  • Bupropion: dopamine/norepinephrine reuptake inhibitor; also has nicotinic antagonism; smoking cessation.
  • Nicotine replacement therapy: patch, gum, lozenge, inhaler, spray.

Anticholinergics (Muscarinic Antagonists)

Used to block muscarinic effects:

  • Benztropine, trihexyphenidyl: Parkinson disease tremor; antipsychotic-induced parkinsonism; significant CNS anticholinergic effects.
  • Oxybutynin, tolterodine, solifenacin, mirabegron (β3 agonist alternative): overactive bladder.
  • Scopolamine: motion sickness, postop nausea; transdermal patch behind ear.
  • Glycopyrrolate: peripheral antimuscarinic; for sialorrhea, secretion management.
  • Atropine: bradycardia, organophosphate poisoning, secretions.
  • Ipratropium, tiotropium: pulmonary; minimal CNS.
  • Older tricyclic antidepressants, paroxetine: incidental anticholinergic activity.
  • Many antihistamines (diphenhydramine, hydroxyzine): anticholinergic.
  • Adverse effects: anticholinergic burden — cognitive decline, falls, urinary retention, constipation, delirium.

Neuromuscular Blockers

  • Non-depolarizing: vecuronium, rocuronium, atracurium, cisatracurium. Reversed by acetylcholinesterase inhibitors (neostigmine + glycopyrrolate) or sugammadex (chelates rocuronium/vecuronium directly).
  • Depolarizing: succinylcholine. Rapid onset; complications include malignant hyperthermia (with halogenated anesthetics, RYR1 mutation), hyperkalemia (severe in burns, denervation), and rare adverse reactions.
  • For RSI, ICU paralysis, surgical operations.

Cholinergic Toxicology

Cholinergic Crisis (Excess ACh)

  • SLUDGE: salivation, lacrimation, urination, defecation, GI cramps, emesis.
  • Plus muscle fasciculations, bradycardia, miosis, bronchospasm.
  • Caused by AChE inhibitor overdose (pyridostigmine, donepezil, organophosphates, nerve agents).
  • Treatment: atropine (muscarinic antagonist), pralidoxime (reactivates AChE in organophosphate poisoning).

Anticholinergic Toxidrome

  • “Mad as a hatter, red as a beet, hot as a hare, dry as a bone, blind as a bat” — confusion, flush, hyperthermia, dry mucous membranes, mydriasis.
  • Caused by intentional or accidental anticholinergic overdose (jimson weed, antihistamines, scopolamine, TCAs, atropine).
  • Treatment: supportive; physostigmine in severe cases (cardiac monitoring).

Organophosphate Poisoning

  • Irreversible AChE inhibition (organophosphates, nerve agents, some pesticides).
  • Acute: SLUDGE + paralysis.
  • Subacute/intermediate: muscle weakness, respiratory failure (24-96 hours).
  • Delayed neuropathy: 2-3 weeks after.
  • Treatment: atropine large doses, pralidoxime, intubation if needed.

Clinical Applications by Disease

Alzheimer Disease and DLB

  • Cholinergic deficit hypothesis: degeneration of basal forebrain cholinergic neurons; loss of cortical ACh.
  • Donepezil, rivastigmine, galantamine: symptomatic benefit.
  • Rivastigmine particularly effective in DLB and PD dementia.
  • Modest effect; symptom modifiers.
  • Combination with memantine (NMDA antagonist) in moderate-severe AD.

Myasthenia Gravis

  • Autoimmune disease against acetylcholine receptor (AChR) at neuromuscular junction.
  • Pyridostigmine: symptomatic (prolongs ACh action at neuromuscular junction).
  • Disease-modifying: immunosuppression (steroids, azathioprine, mycophenolate, eculizumab, efgartigimod, rozanolixizumab, ravulizumab).
  • Cholinergic crisis: pyridostigmine overdose → SLUDGE + paradoxical muscle weakness.
  • Myasthenic crisis: undertreated; respiratory failure.

Lambert-Eaton Myasthenic Syndrome

  • Presynaptic Ca²⁺ channel autoantibodies.
  • 3,4-diaminopyridine (amifampridine): blocks K⁺ channels → prolongs depolarization → more Ca²⁺ → more ACh release.
  • Often paraneoplastic (small cell lung cancer).

Botulism

  • Botulinum toxin: cleaves SNARE proteins → blocks ACh release at neuromuscular junction.
  • Clinical: descending paralysis, autonomic dysfunction.
  • Treatment: botulinum antitoxin.
  • Botulinum toxin therapy (botulinumtoxinA, botulinumtoxinB) used for dystonia, spasticity, migraine, hyperhidrosis, blepharospasm.

Therapeutic Use of Anticholinergics in Neurology

  • Sialorrhea (Parkinson, ALS): glycopyrrolate (limits CNS effects).
  • Tremor (essential or PD): benztropine (less commonly used; CNS effects).
  • Neuroleptic-induced parkinsonism: benztropine.
  • Acute dystonic reaction: diphenhydramine or benztropine.
  • Pseudobulbar pseudo-secretions: scopolamine patch.

🔍 Did You Know?

The cholinergic hypothesis of Alzheimer disease — that AD results from progressive degeneration of basal forebrain cholinergic neurons and the resulting cortical cholinergic deficit — was the dominant theory for decades and led to the development of acetylcholinesterase inhibitors as the first symptomatic treatments. While this hypothesis is now understood to be only one component of AD’s complex pathology (with amyloid, tau, neuroinflammation, and other systems contributing), the cholinergic deficit remains real and clinically significant. The basal forebrain cholinergic neurons — particularly the nucleus basalis of Meynert — degenerate progressively in AD, and the cortical loss of cholinergic input contributes to attention, memory, and executive function decline. Modern data has refined the understanding: some patients respond better than others to cholinergic boosting, and there are biomarker-based approaches to identifying which patients have predominant cholinergic deficits. The therapeutic benefit of donepezil, rivastigmine, and galantamine is modest and time-limited, but for individual patients can be meaningful — the cognitive benefit equates to roughly 4-6 months of “extra time” before equivalent disease progression. The lesson generalizes: neurotransmitter pharmacology often delivers symptomatic relief but does not address underlying disease pathology, and the gap between symptomatic and disease-modifying therapy remains a critical frontier in neurology.

Pitfalls and Pearls

  • Nicotinic vs muscarinic: nicotinic at NMJ and ganglia; muscarinic at parasympathetic effectors and CNS cognition.
  • AChE inhibitors for AD: donepezil, rivastigmine, galantamine; symptom modifiers, modest benefit.
  • Pyridostigmine for MG: oral mainstay; q4-6h.
  • Rivastigmine for DLB/PD dementia: particularly effective.
  • Anticholinergic burden: cumulative; cognitive decline risk in elderly.
  • Avoid anticholinergics in dementia unless absolutely necessary.
  • Glycopyrrolate for sialorrhea: limited CNS effects (charged molecule).
  • Cholinergic crisis: SLUDGE + atropine.
  • Anticholinergic toxidrome: confusion + flush + hyperthermia; physostigmine in severe cases.
  • Organophosphate poisoning: atropine + pralidoxime.
  • Neuromuscular blockers: reversed by neostigmine + glycopyrrolate or sugammadex.
  • Botulinum toxin: cleaves SNARE; therapeutic uses in dystonia, spasticity, migraine.
  • Varenicline: nicotinic partial agonist for smoking cessation.
  • Donepezil/AChE inhibitors: bradycardia risk; check ECG and history of conduction disease.

References

  1. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw-Hill; 2023.
  2. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 2011;221(2):555-563.
  3. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
  4. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797-1810.
  5. Bird SB, Sutherland TJ, Gresham C, Oakeshott J, Scott C. OP-IDN: poisoning by organophosphorus compounds. Clin Toxicol (Phila). 2008;46(4):341-345.
  6. Cummings JL, Cooper-Reid GS. Anticholinergic medications and cognitive impairment in older adults. Drugs Aging. 2020;37(7):501-517.